Novartis AG
CRYSTALLINE FORMS OF A TLR7/TLR8 INHIBIT0R

Abstract:

This application relates to various crystalline forms of (S)--N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,- 6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1- -yl)morpholine-3-carboxamide in its free-form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ("hydrates"). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjogren's syndrome, arthritis, rheumatoid arthritis and psoriasis.